JP Morgan Chase
LABP

JP Morgan Chase’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

JP Morgan Chase’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-59
Closed -$1.27K – 7906
2024
Q1 		$1.27K Hold
59
– – ﹤0.01% 6624
2023
Q4 		$216 Hold
59
– – ﹤0.01% 7040
2023
Q3 		$228 Hold
59
– – ﹤0.01% 6830
2023
Q2 		$247 Sell
59
-2
-3% -$6 ﹤0.01% 6614
2023
Q1 		$0 Hold
61
– – ﹤0.01% 7435
2022
Q4 		$0 Sell
61
-163
-73% -$624 ﹤0.01% 7223
2022
Q3 		$1K Buy
224
+51
+29% +$443 ﹤0.01% 6405
2022
Q2 		$1K Sell
173
-29,065
-99% -$264K ﹤0.01% 6413
2022
Q1 		$432K Sell
29,238
-724
-2% -$18.4K ﹤0.01% 4794
2021
Q4 		$1.44M Sell
29,962
-1,037
-3% -$109K ﹤0.01% 4113
2021
Q3 		$4.53M Sell
30,999
-6,484
-17% -$842K ﹤0.01% 3119
2021
Q2 		$4.33M Sell
37,483
-19
-0.1% -$2.12K ﹤0.01% 3175
2021
Q1 		$3.61M Buy
+37,502
New +$4.89M ﹤0.01% 3247

JP Morgan Chase's LABP Position: Q2 2024 in Review

JP Morgan Chase sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 59 shares — an estimated $1.27K sold.

JP Morgan Chase first reported a position in LABP in Q1 2021 and held it in 13 quarters. The position peaked at $4.53M in Q3 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

  • JP Morgan Chase reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 59 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $1.27K.
  • JP Morgan Chase first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • JP Morgan Chase's Landos Biopharma, Inc. Common Stock position peaked at $4.53M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.